MHC class I antigen processing pathway defects, ras mutations and disease stage in colorectal carcinoma
Open Access
- 22 December 2003
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 109 (2) , 265-273
- https://doi.org/10.1002/ijc.11681
Abstract
Colorectal tumorigenesis has been associated with the progressive acquisition of a variety of genetic alterations. These include mutations of the Ki‐ras proto‐oncogene in codons 12 and 13, which account for 85% of genetic changes in colorectal cancer. In murine in vitro models of oncogenic transformation, an association between ras‐mediated transformation and downregulation of different components of the MHC class I antigen processing machinery (APM) has been described. In order to investigate whether this association also exists in human tumors, 10 cases of high‐grade intraepithelial neoplasia (HIN), as well as primary tumors and autologous lymph node metastases from 42 patients with colorectal carcinoma, were monitored by allele‐specific restriction analysis for Ki‐ras mutations. In parallel, APM component expression and tumor cell proliferation were analyzed by immunohistochemistry. In comparison to autologous colorectal mucosa, TAP1, LMP2 and tapasin loss was found in 68%, 67% and 80% of HIN, respectively. In contrast, impaired TAP1, LMP2 and tapasin expression was found in 42%, 42% and 63% of primary adenocarcinomas of stage III disease and in 63%, 47% and 79% of the matched lymph node metastases, respectively. More than 60% of colorectal tumor lesions with TAP1, LMP2 and/or tapasin defects displayed Ki‐ras mutations. The frequency of TAP1, LMP2 and tapasin loss varied between 33% of primary adenocarcinomas, 40% of HIN to approximately 67% of metastases. These data suggest that i) APM component deficiencies occur more frequently in Ki‐ras‐mutated colorectal carcinoma lesions and ii) APM abnormalities in conjunction with Ki‐ras mutations appear to be associated with disease stage. These findings support the hypothesis that Ki‐ras mutations may contribute to immune escape mechanisms of tumors by downregulating the MHC class I APM component expression.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (SFB432, project A5)
This publication has 45 references indexed in Scilit:
- A Single-nucleotide Deletion Leads to Rapid Degradation ofTAP-1 mRNA in a Melanoma Cell LinePublished by Elsevier ,2003
- Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: β2‐microglobulin inactivation in MSI‐positive tumors and LMP7/TAP2 downregulation in MSI‐negative tumorsTissue Antigens, 2003
- Use of Spontaneous Epstein-Barr Virus-Lymphoblastoid Cell Lines Genetically Modified to Express Tumor Antigen as Cancer Vaccines: Mutated p21rasOncogene in Pancreatic Carcinoma as a ModelHuman Gene Therapy, 2002
- Mutations of the β2‐microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptidesTissue Antigens, 1998
- Mechanisms of loss of HLA class I expression on colorectal tumor cellsTissue Antigens, 1996
- Functional expression and purification of the ABC transporter complex associated with antigen processing (TAP) in insect cellsFEBS Letters, 1994
- Natural history of HLA expression during tumour developmentImmunology Today, 1993
- K‐ras mutations (codon 12) are not involved in down‐regulation of mhc class‐i genes in colon carcinomasInternational Journal of Cancer, 1990
- Genetic Alterations during Colorectal-Tumor DevelopmentNew England Journal of Medicine, 1988